Rhythm Pharmaceuticals, Inc. RYTM
We take great care to ensure that the data presented and summarized in this overview for RHYTHM PHARMACEUTICALS, INC. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding RYTM
View all-
Black Rock Inc. New York, NY6.74MShares$420 Million0.01% of portfolio
-
Ra Capital Management, L.P. Boston, MA6.08MShares$379 Million6.69% of portfolio
-
Primecap Management CO Pasadena, CA5.79MShares$361 Million0.26% of portfolio
-
Baker Bros. Advisors LP New York, NY5.6MShares$349 Million3.54% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.44MShares$215 Million0.0% of portfolio
-
Nea Management Company, LLC Timonium, MD2.91MShares$181 Million14.62% of portfolio
-
Perceptive Advisors LLC New York, NY2.55MShares$159 Million5.65% of portfolio
-
State Street Corp Boston, MA1.97MShares$123 Million0.0% of portfolio
-
Janus Henderson Group PLC London, X01.66MShares$103 Million0.05% of portfolio
-
Goldman Sachs Group Inc New York, NY1.64MShares$102 Million0.01% of portfolio
Latest Institutional Activity in RYTM
Top Purchases
Top Sells
About RYTM
Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of rare genetic diseases of obesity. The company's lead product candidate is IMCIVREE, a potent melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is also developing setmelanotide, which is in Phase II clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, Smith-Magenis syndrome obesity, POMC epigenetic disorders, and other MC4R disorders. Rhythm Pharmaceuticals, Inc. has a collaborative research agreement with the Clinical Registry Investigating Bardet-Biedl Syndrome. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.
Insider Transactions at RYTM
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Apr 29
2025
|
Yann Mazabraud EVP, Head of International |
SELL
Open market or private sale
|
Direct |
6,745
-15.19%
|
$438,425
$65.08 P/Share
|
|
Apr 29
2025
|
Pamela J. Cramer Chief Human Resources Officer |
SELL
Open market or private sale
|
Direct |
7,031
-26.8%
|
$457,015
$65.09 P/Share
|
|
Apr 29
2025
|
Pamela J. Cramer Chief Human Resources Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
7,031
+21.13%
|
$42,186
$6.8 P/Share
|
|
Apr 15
2025
|
Yann Mazabraud EVP, Head of International |
BUY
Exercise of conversion of derivative security
|
Direct |
11,405
+20.44%
|
-
|
|
Apr 14
2025
|
Yann Mazabraud EVP, Head of International |
BUY
Exercise of conversion of derivative security
|
Direct |
10,375
+23.92%
|
-
|
|
Apr 08
2025
|
Yann Mazabraud EVP, Head of International |
SELL
Open market or private sale
|
Direct |
17,750
-25.03%
|
$1,065,000
$60.96 P/Share
|
|
Apr 08
2025
|
Pamela J. Cramer Chief Human Resources Officer |
SELL
Open market or private sale
|
Direct |
20,760
-16.25%
|
$1,224,840
$59.84 P/Share
|
|
Apr 08
2025
|
Pamela J. Cramer Chief Human Resources Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
20,760
+22.03%
|
$352,920
$17.08 P/Share
|
|
Mar 21
2025
|
Christopher Paul German Corporate Controller & CAO |
SELL
Open market or private sale
|
Direct |
344
-10.64%
|
$18,576
$54.23 P/Share
|
|
Mar 20
2025
|
Christopher Paul German Corporate Controller & CAO |
BUY
Exercise of conversion of derivative security
|
Direct |
1,163
+26.46%
|
-
|
|
Mar 14
2025
|
Yann Mazabraud EVP, Head of International |
SELL
Open market or private sale
|
Direct |
75,000
-37.33%
|
$3,825,000
$51.26 P/Share
|
|
Mar 14
2025
|
Yann Mazabraud EVP, Head of International |
BUY
Exercise of conversion of derivative security
|
Direct |
75,000
+39.4%
|
$1,650,000
$22.28 P/Share
|
|
Feb 19
2025
|
Hunter C Smith Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
2,215
-1.98%
|
$126,255
$57.22 P/Share
|
|
Feb 19
2025
|
Christopher Paul German Corporate Controller & CAO |
SELL
Open market or private sale
|
Direct |
635
-23.48%
|
$36,195
$57.22 P/Share
|
|
Feb 19
2025
|
Jennifer Chien EVP, Head of North America |
SELL
Open market or private sale
|
Direct |
2,035
-25.78%
|
$115,995
$57.22 P/Share
|
|
Feb 19
2025
|
David P Meeker President and CEO |
SELL
Open market or private sale
|
Direct |
9,896
-4.69%
|
$564,072
$57.22 P/Share
|
|
Feb 19
2025
|
Joseph Shulman Chief Technical Officer |
SELL
Open market or private sale
|
Direct |
1,228
-12.61%
|
$69,996
$57.22 P/Share
|
|
Feb 19
2025
|
Pamela J. Cramer Chief Human Resources Officer |
SELL
Open market or private sale
|
Direct |
982
-4.86%
|
$55,974
$57.22 P/Share
|
|
Feb 16
2025
|
Hunter C Smith Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
6,600
+5.56%
|
-
|
|
Feb 16
2025
|
Christopher Paul German Corporate Controller & CAO |
BUY
Exercise of conversion of derivative security
|
Direct |
1,807
+40.05%
|
-
|
Last 12 Months Summary
| Exercise of conversion of derivative security | 507K shares |
|---|
| Open market or private sale | 451K shares |
|---|